Based on FP-Growth Algorithm to Excavate Medication Rule of Chinese Materia Medica for Radiation Esophagitis

Objective:To find the medication rule of Chinese materia medica for treating radiation esophagitis through FP-Growth algorithm.Methods:By searching the three major literature databases such as Chinese Journal Full-text Database,VIP Chinese Sci-tech Journals Database,Wanfang Data,etc.from the database establishment to May 10,2020,88 effective documents and 91 prescriptions were screened.The medication frequency of prescription in the paper was extracted and sorted.Results:The frequency of medicinal property from high to low were:slightly cold,cold,balance,warm,cool,slightly warm,and great cold.The frequency of medicinal taste from high to low were:sweet,bitter,pungent,slightly bitter,salty,slightly pungent,sour,light,astringent.The frequency of channel tropism from high to low were:lung,stomach,liver,heart,spleen,etc.,and 10 herbal combinations with clinical significance were obtained.There was one prescription with good correlation strength in the clinical treatment of radiation esophagitis.Conclusion:The medication rule of Chinese materia medica for the treatment of radiation esophagitis is based on the principles of clearing away heat and detoxification,benefiting Qi(气)and nourishing Yin(阴),and stopping bleeding and removing phlegm.Heat-clearing medicine,tonic medicine,phlegmresolving,cough–relieving medicine and asthma-relieving medicine,blood-activating and stasis removing medicine were highly frequent used.The high-frequency association rules are nourishing Yin–clearing heat–generating fluid,removing toxin–cooling blood–benefiting Qi,benefiting Qi–invigorating spleen–stopping bleeding.It is stable and feasible to use FP-Growth algorithm to mine traditional Chinese medicine(TCM)to treat diseases.

ACUPUNCTURE AT JIANJING FOR TREATMENT OF ACHALASIA OF THE CARDIA

Achalasia of the cardia,also known ascardiospasm or megalo—esophagus,Is char-acterized by the symptom of dysphagia.Diagnosis of the disease and its division intodifferent types are described in the PracticalTextbook of Medicine and Symposium onMedicine.During the recent 10 years,theauthor treated 21 cases of the disease byacupuncture with satisfactory results as re-ported in the following.

Crotonylation of PRKACA enhances PKA activity and promotes colorectal cancer development via the PKA-FAK-AKT pathway

Colorectal cancer (CRC) is a common cancer with high morbidity and mortality.1 Post-translational modification (PTM) of protein plays an important role in the pathogenesis of CRC. Lysine crotonylation (Kcr) is an important type of PTM and has been proved evolutionarily conserved in eukaryotic cells from a wide range of species.2 However, the role of protein Kcr in the progression of CRC is unclear.

Highly sensitive light-up near-infrared fluorescent probe for detection and imaging of β-glucuronidase in human serum,living cells and tumor-bearing mice

β-Glucuronidase(GUS)plays a key role in tumor initiation,metastasis,and progression,and thus,has been proposed as a promising cancer biomarker.In this study,we designed an enzyme-activatable near-infrared(NIR)fluorescent probe(DCM-βGlcA)for the rapid and accurate detection of GUS activity in vitro,in vivo and ex vivo.The DCM-βGlcA was prepared by linking a glucuronic acid residue to dicyanomethylene-4 H-pyran(DCM).This probe exhibited significant light-up NIR fluorescent signals at 680 nm after reacting with GUS and the Stokes shift could reach 150 nm.The DCM-βGlcA showed a high sensitivity toward GUS and an excellent linear relationship at concentrations ranging between 0 and 4 U L^(-1)(R^(2)=0.9974)with the limit of detection as low as 0.19 U L^(-1).We used the DCM-βGlcA to identify GUS serum levels in both cancer patients and healthy individuals with a similar accuracy as that of an enzyme-linked immunosorbent assay(ELISA)while being easier and faster to perform.Moreover,the DCM-βGlcA was used for tracking endogenous GUS in living cells,thereby discriminating GUSoverexpressed liver cancer from normal cells.Additionally,the DCM-βGlcA was able to detect and image endogenous GUS in liver cancer tissue and tumor-bearing mouse models.These findings demonstrate the potential of the DCM-βGlcA as a promising tool for detecting and monitoring GUS activity in preclinical applications.